These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19153360)

  • 1. Severe symptomatic hypocalcemia in a patient with RDEB treated with intravenous zoledronic acid.
    Perman MJ; Lucky AW; Heubi JE; Azizkhan RG
    Arch Dermatol; 2009 Jan; 145(1):95-6. PubMed ID: 19153360
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe hypocalcemia associated with zoledronic acid treatment in a patient with a risk of fracture due to drug-induced osteopenia.
    Cure E; Yuce S; Cure MC
    Minerva Endocrinol; 2013 Jun; 38(2):217-8. PubMed ID: 23732377
    [No Abstract]   [Full Text] [Related]  

  • 3. Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake?
    Ho JW; Sundar S
    Clin Genitourin Cancer; 2012 Mar; 10(1):50-3. PubMed ID: 22245101
    [No Abstract]   [Full Text] [Related]  

  • 4. High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid.
    Zuradelli M; Masci G; Biancofiore G; Gullo G; Scorsetti M; Navarria P; Tancioni F; Berlusconi M; Giordano L; Santoro A
    Oncologist; 2009 May; 14(5):548-56. PubMed ID: 19411682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptomatic hypocalcemia following intravenous administration of zoledronic acid in a breast cancer patient.
    Mishra A
    J Postgrad Med; 2008; 54(3):237. PubMed ID: 18626181
    [No Abstract]   [Full Text] [Related]  

  • 6. Tonic-clonic seizure as the presentation symptom of severe hypocalcemia secondary to zoledronic acid administration.
    Navarro M; López R; Alaña M; Ocaña A; Leno R; Sánchez F; Fonseca E; Cruz JJ
    J Palliat Med; 2007 Dec; 10(6):1226-7. PubMed ID: 18095793
    [No Abstract]   [Full Text] [Related]  

  • 7. Acute phase response and mineral status following low dose intravenous zoledronic acid in children.
    Munns CF; Rajab MH; Hong J; Briody J; Högler W; McQuade M; Little DG; Cowell CT
    Bone; 2007 Sep; 41(3):366-70. PubMed ID: 17574945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.
    Henley D; Kaye J; Walsh J; Cull G
    Intern Med J; 2005 Dec; 35(12):726-8. PubMed ID: 16313549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypocalcemia and azotemia associated with zoledronic acid and interferon alfa.
    Tanvetyanon T; Choudhury AM
    Ann Pharmacother; 2004 Mar; 38(3):418-21. PubMed ID: 14970365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
    Gulley JL; Wu S; Arlen PM; Dahut WL
    Clin Genitourin Cancer; 2007 Sep; 5(6):403-5. PubMed ID: 17956715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronate Induced Hypocalcemia and Hypophosphatemia in Osteoporosis: A Cause of Concern.
    Kaur U; Chakrabarti SS; Gambhir IS
    Curr Drug Saf; 2016; 11(3):267-9. PubMed ID: 27113952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.
    Patel K; Brahmbhatt V; Ramu V
    Tenn Med; 2005 Feb; 98(2):83-5, 89. PubMed ID: 15779196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unilateral anterior uveitis complicating zoledronic acid therapy in prostate cancer.
    Banal F; Briot K; Ayoub G; Dougados M; Roux C
    J Rheumatol; 2008 Dec; 35(12):2458-9. PubMed ID: 19040323
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
    Smith A; Kressley A; Saif MW
    JOP; 2009 Mar; 10(2):212-4. PubMed ID: 19287122
    [No Abstract]   [Full Text] [Related]  

  • 15. Yearly zoledronic acid in postmenopausal osteoporosis.
    Poole KE; Kaptoge S; Reeve J
    N Engl J Med; 2007 Aug; 357(7):711-2; author reply 714-5. PubMed ID: 17703530
    [No Abstract]   [Full Text] [Related]  

  • 16. Zoledronic acid induced osteonecrosis of tibia and femur.
    Gupta S; Jain P; Kumar P; Parikh PM
    Indian J Cancer; 2009; 46(3):249-50. PubMed ID: 19574685
    [No Abstract]   [Full Text] [Related]  

  • 17. Biennial [corrected] IV zoledronic acid (Reclast) for prevention of osteoporosis.
    Med Lett Drugs Ther; 2009 Jun; 51(1315):49. PubMed ID: 19556940
    [No Abstract]   [Full Text] [Related]  

  • 18. Orbital inflammation after use of zoledronic acid for metastasized prostate carcinoma.
    Missotten G; Verheezen Y
    Bull Soc Belge Ophtalmol; 2010; (315):23-4. PubMed ID: 21110506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe resistant hypocalcemia in multiple myeloma after zoledronic acid administration: a case report.
    Noriega Aldave AP; Jaiswal S
    J Med Case Rep; 2014 Oct; 8():353. PubMed ID: 25342294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.